Viemed Healthcare, Inc.
NASDAQ:VMDMedical - Devices
+$0.07 today
- Market cap
- $332.70M
- Beta
- 1.13
- P/E (TTM)
- 27.4
- EPS (TTM)
- $0.39
Volume 0.26M
Average 0.26M
VMD Interest Expense
Cost of servicing the company's debt during the period.
Viemed Healthcare, Inc.NASDAQ: VMD
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense growth accelerates
Q1 FY2026 interest expense of $305K rose 70.4% year over year, ahead of the +62.5% change in trailing-twelve-month interest expense. Sequentially, it fell 16.2% from the prior quarter. Over 3 fiscal years it compounded at +81.7% a year.
Context
- Interest expense amounted to 0.4% of revenue in FY2025, unchanged from a year earlier.
- Interest expense increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +70.4% holds above the trailing-twelve-month pace of +62.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 1.18M USD
- Year-over-year change
- +52.3%
- 4-year CAGR
- +38.9%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.18M | +52.3% |
| FY2024 | 2024-12-31 | 776K | +83.0% |
| FY2023 | 2023-12-31 | 424K | +115.2% |
| FY2022 | 2022-12-31 | 197K | -38.1% |
| FY2021 | 2021-12-31 | 318K | — |
Interest Expense vs competitors
How VMD compares with its peers on the latest reported figures
- VMD's LTM Mar 2026 interest expense of $1.31M is the 6th highest of the 11 companies compared; the peer median is $1.38M.
- Its year-over-year change of +62.5% is the highest of 6, against a peer median of -44.7%.
- Interest expense amounts to 0.5% of revenue for VMD, versus a peer median of 2.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.02M | -67.3% | +57.6% | 6.0% | |
| LTM Mar 2026 | $5.92M | +21.0% | +228.1% | 10.0% | |
| LTM Mar 2026 | $4.94M | -58.6% | -23.8% | 11.1% | |
| LTM Mar 2026 | $4.71M | -39.7% | -35.8% | 11.6% | |
| LTM Mar 2026 | $2.61M | -44.7% | +4.8% | 3.3% | |
| LTM Mar 2026 | $1.31M | +62.5% | +81.7% | 0.5% | |
| LTM Dec 2025 | $149K | — | — | 1.1% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding VMD) | $1.38M | -44.7% | +4.8% | 2.2% | |
Competitors are the stored peer set for VMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 117.06M | 138.83M | 183.01M | 224.26M | 270.28M |
| Cost of Revenue | 43.65M | 54.15M | 70.23M | 91.05M | 114.82M |
| Gross Profit | 73.41M | 84.68M | 112.78M | 133.2M | 155.46M |
| Gross Margin | 62.7% | 61.0% | 61.6% | 59.4% | 57.5% |
| Research & Development | 2.11M | 2.7M | 2.78M | 3.07M | 3.02M |
| Selling, General & Admin | 60.04M | 73.36M | 93.73M | 112.48M | 130.5M |
| Operating Expenses | 61.83M | 76.43M | 98.45M | 115.3M | 134.75M |
| Depreciation & Amortization | 11.31M | 15.63M | 21.86M | 25.37M | 28.61M |
| EBITDA | 24.13M | 24.82M | 36.68M | 42.31M | 51.56M |
| EBITDA Margin | 20.6% | 17.9% | 20.0% | 18.9% | 19.1% |
| Operating Income | 11.58M | 8.25M | 14.33M | 17.9M | 20.71M |
| Operating Margin | 9.9% | 5.9% | 7.8% | 8.0% | 7.7% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 318K | 197K | 424K | 776K | 1.18M |
| Other Income / Expenses | 923K | 738K | 61K | (1.73M) | 1.06M |
| Income Before Tax | 12.5M | 8.99M | 14.39M | 16.17M | 21.77M |
| Pre-Tax Margin | 10.7% | 6.5% | 7.9% | 7.2% | 8.1% |
| Income Tax Expense | 3.38M | 2.77M | 4.15M | 4.76M | 6.39M |
| Net Income | 9.13M | 6.22M | 10.24M | 11.27M | 14.93M |
| Net Margin | 7.8% | 4.5% | 5.6% | 5.0% | 5.5% |
| EPS (Basic) | 0.23 | 0.15 | 0.27 | 0.29 | 0.38 |
| EPS (Diluted) | 0.22 | 0.15 | 0.25 | 0.28 | 0.37 |
| Weighted Avg Shares | 39.49M | 38.66M | 38.35M | 38.76M | 38.9M |
| Weighted Avg Shares (Diluted) | 40.68M | 39.81M | 40.38M | 40.81M | 40.82M |
Viemed Healthcare, Inc.
NASDAQ:VMD
Intrinsic Alpha fair value
Locked
Current Price
$8.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.